Innoviva
INVA | NASDAQ
$18.49
-$0.54 (-2.84%)
At close: Nov 16, 2026, 4:00 PM ET
$18.49
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Innoviva Company Profile
Company profile explainedCompany Profile
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Key Executives
| Name | Position |
|---|---|
| Pavel Raifeld | Chief Executive Officer & Director |
| Stephen Basso | Chief Financial Officer |
| David Altarac | Chief Medical Officer of IST |
| Marianne Zhen | Chief Accounting Officer & Secretary |
| Patricia Drake | Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 24, 2026 | 4 | Filing |
| Aug 24, 2026 | 4 | Filing |
| Aug 24, 2026 | 4 | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 31, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| May 22, 2026 | 4 | Filing |
| May 22, 2026 | 4 | Filing |
| May 22, 2026 | 4 | Filing |
Innoviva
| Country | United States |
| IPO Date | Oct 5, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 159 |
| CEO | Pavel Raifeld |
Contact Details
1350 Old Bayshore Highway Burlingame,
California 94010 United States
Stock Details
| Ticker Symbol | INVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001080014 |
| CUSIP Number | 45781M101 |
| ISIN Number | US45781M1018 |
| SIC Code | 2834 |
Recent News
- 6 days ago / zacks.comIs Innoviva (INVA) Stock Undervalued Right Now?
- 8 days ago / zacks.comINVA or MRK: Which Is the Better Value Stock Right Now?
- 12 days ago / zacks.comInnoviva (INVA) Tops Q3 Earnings Estimates
- 29 days ago / businesswire.comInnoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
- 1 month ago / zacks.comDo Options Traders Know Something About Innoviva Stock We Don't?
- 1 month ago / zacks.comINVA vs. MRK: Which Stock Is the Better Value Option?
- 1 month ago / zacks.comShould Value Investors Buy Innoviva (INVA) Stock?
- 3 months ago / seekingalpha.comInnoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic
- 3 months ago / zacks.comInnoviva (INVA) Q2 Earnings and Revenues Top Estimates
- 5 months ago / businesswire.comNortiva Bio Launches to Develop Long-Acting Oral Medicines
Add to Watchlist
Select watchlists to add or remove INVA